Hospital & Healthcare Services · Founded 2004 · www.artemishospitals.com · BSE 542919 · NSE ARTEMISMED · ISIN INE025R01021
No Notes Added Yet
Business
Artemis Medicare Services Ltd. is a leading private healthcare provider primarily operating in India. The company owns and operates multi-specialty tertiary care hospitals, with its flagship facility located in Gurugram, Haryana. Its core business model revolves around providing comprehensive medical services across various specialties including cardiology, oncology, neurosciences, orthopaedics, gastroenterology, and emergency medicine. Artemis generates revenue primarily through patient services, including inpatient admissions, outpatient consultations, diagnostic tests, surgical procedures, and pharmacy sales. It caters to both domestic and international patients.
Revenue Mix
The company's revenue is predominantly derived from its hospital operations. While specific revenue mix percentages for different specialties are not consistently public, the primary streams include:
Inpatient Services: Admissions for complex medical conditions, surgeries, and long-term care.
Outpatient Services: Consultations, day care procedures, and follow-up visits.
Diagnostics: Laboratory tests and imaging services (e.g., MRI, CT scans).
Pharmacy: In-hospital pharmacy sales to patients.
The company operates primarily through its flagship hospital and aims for high utilization across its bed capacity.
Industry
The Indian hospital and healthcare services industry is large, growing, and fragmented, with a mix of large corporate chains, smaller regional players, and standalone hospitals. It is driven by factors like increasing health consciousness, rising disposable incomes, improving insurance penetration, and medical tourism. Artemis Medicare Services Ltd. is positioned as a quality-focused, tertiary care provider, particularly strong in the Delhi-NCR region. It competes with other established corporate hospital chains like Max Healthcare, Fortis Healthcare, Apollo Hospitals, and Medanta, distinguishing itself through its emphasis on medical technology, clinical expertise, and patient experience. Its single-hospital focus (primarily Gurugram) gives it deep roots in that market but limits its national footprint compared to multi-city chains.
MOAT
Brand & Reputation: Artemis has built a strong brand reputation in the Gurugram and Delhi-NCR region for specialized medical care, particularly in certain high-end specialties. This attracts both local and international patients.
Clinical Excellence & Talent: A focus on attracting and retaining highly skilled medical professionals and adopting advanced medical technologies contributes to its service quality.
Infrastructure & Accreditation: Its modern infrastructure and NABH accreditation underscore its commitment to quality and patient safety, which can act as a differentiator.
Regional Concentration: While not a national scale, its strong concentration and established presence in a key metropolitan area allow for deeper market penetration and operational efficiencies within that region.
Growth Drivers
Rising Healthcare Expenditure: Increasing per capita healthcare spending and health insurance penetration in India.
Medical Tourism: Gurugram's proximity to Delhi makes it a hub for medical tourism, attracting international patients for high-quality, cost-effective treatment.
Demographic Shifts & Disease Burden: Growing elderly population and increasing prevalence of non-communicable diseases (NCDs) create sustained demand for specialized tertiary care.
Infrastructure Expansion: Potential for bed capacity expansion or adding new specialized units within its existing or future facilities.
Digital Health Integration: Adoption of telemedicine and digital health platforms to improve patient access and operational efficiency.
Risks
Intense Competition: Highly competitive market with established players and new entrants leading to pricing pressures and talent wars.
Regulatory & Policy Changes: The healthcare sector is subject to stringent regulations, and changes in pricing caps, quality standards, or accreditation norms can impact profitability.
Talent Retention: Attracting and retaining skilled doctors, nurses, and allied healthcare professionals is crucial and can lead to high employee costs.
High Capital Expenditure: Setting up and maintaining modern hospitals requires significant capital investment and ongoing technology upgrades.
Medical Malpractice & Litigation: Risk of medical errors and associated legal liabilities, which can harm reputation and finances.
Disease Outbreaks: Pandemics or epidemics can significantly impact patient footfall for elective procedures and operational costs.
Management & Ownership
Artemis Medicare Services Ltd. is promoted by the Emami Group, a diversified Indian conglomerate with interests across various sectors. The promoter group holds a significant stake, indicating their long-term commitment to the business. The management team consists of experienced professionals from the healthcare industry, overseeing operations, clinical excellence, and strategic growth initiatives. The presence of a well-established promoter group often lends credibility and financial backing.
Outlook
Artemis Medicare Services Ltd. is well-positioned to benefit from the robust growth in India's healthcare sector, driven by increasing demand for quality medical services, rising health awareness, and the potential for medical tourism. Its strong brand presence and clinical focus in the Delhi-NCR region provide a solid foundation. However, the company operates in a highly competitive and capital-intensive industry, facing challenges such as intense competition, evolving regulatory landscape, and the constant need for technological upgrades and talent retention. Its ability to expand strategically, optimize operational efficiencies, and maintain its clinical reputation will be key to its sustained growth and profitability amidst a dynamic market.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 225 | 223 | 241 | 232 | 240 | 255 | 275 | 272 | 279 | 287 |
| Other Income | 2 | 4 | 7 | 9 | 12 | 7 | 8 | 7 | 8 | 5 |
| Total Income | 227 | 228 | 249 | 241 | 252 | 262 | 282 | 280 | 287 | 293 |
| Total Expenditure | 187 | 187 | 199 | 195 | 204 | 214 | 224 | 228 | 228 | 231 |
| Operating Profit | 40 | 41 | 50 | 46 | 48 | 48 | 58 | 52 | 59 | 62 |
| Interest | 9 | 8 | 8 | 8 | 8 | 7 | 7 | 7 | 6 | 6 |
| Depreciation | 11 | 11 | 11 | 11 | 12 | 11 | 12 | 12 | 13 | 13 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3 | 0 | 0 |
| Profit Before Tax | 20 | 22 | 31 | 27 | 29 | 30 | 39 | 30 | 40 | 43 |
| Provision for Tax | 6 | 5 | 8 | 6 | 6 | 9 | 9 | 8 | 10 | 11 |
| Profit After Tax | 14 | 17 | 22 | 21 | 23 | 21 | 30 | 22 | 30 | 31 |
| Adjustments | -0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | -0 | -0 |
| Profit After Adjustments | 14 | 17 | 22 | 21 | 23 | 21 | 30 | 22 | 30 | 31 |
| Adjusted Earnings Per Share | 1 | 1.2 | 1.6 | 1.5 | 1.7 | 1.5 | 2.2 | 1.4 | 1.9 | 2 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 547 | 565 | 408 | 555 | 737 | 879 | 937 | 1081 | 1113 |
| Other Income | 4 | 5 | 4 | 5 | 7 | 7 | 33 | 30 | 28 |
| Total Income | 551 | 570 | 412 | 560 | 745 | 886 | 970 | 1111 | 1142 |
| Total Expenditure | 483 | 504 | 373 | 488 | 643 | 746 | 785 | 893 | 911 |
| Operating Profit | 68 | 66 | 39 | 71 | 101 | 140 | 185 | 218 | 231 |
| Interest | 11 | 13 | 13 | 12 | 20 | 31 | 32 | 28 | 26 |
| Depreciation | 20 | 23 | 22 | 22 | 31 | 40 | 45 | 48 | 50 |
| Exceptional Income / Expenses | 0 | 0 | 3 | 0 | 0 | 0 | 0 | -3 | -3 |
| Profit Before Tax | 37 | 31 | 8 | 37 | 51 | 68 | 108 | 139 | 152 |
| Provision for Tax | 16 | 11 | 1 | 6 | 13 | 19 | 25 | 35 | 38 |
| Profit After Tax | 20 | 19 | 6 | 31 | 38 | 49 | 82 | 104 | 113 |
| Adjustments | 0 | 0 | 0 | 0 | 1 | -0 | 0 | -0 | 0 |
| Profit After Adjustments | 20 | 20 | 6 | 32 | 39 | 49 | 83 | 104 | 113 |
| Adjusted Earnings Per Share | 0 | 1.5 | 0.5 | 2.4 | 2.9 | 3.6 | 6 | 6.5 | 7.5 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 15% | 14% | 22% | 0% |
| Operating Profit CAGR | 18% | 29% | 41% | 0% |
| PAT CAGR | 27% | 40% | 77% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 43% | 30% | 56% | NA% |
| ROE Average | 13% | 14% | 13% | 11% |
| ROCE Average | 16% | 16% | 15% | 13% |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 293 | 313 | 320 | 359 | 403 | 448 | 838 | 935 |
| Minority's Interest | -0 | 0 | 2 | 2 | 5 | 6 | 6 | 6 |
| Borrowings | 53 | 66 | 108 | 161 | 214 | 228 | 209 | 190 |
| Other Non-Current Liabilities | 31 | 49 | 61 | 65 | 103 | 135 | 130 | 137 |
| Total Current Liabilities | 177 | 158 | 118 | 138 | 206 | 185 | 216 | 240 |
| Total Liabilities | 554 | 586 | 609 | 726 | 930 | 1002 | 1399 | 1508 |
| Fixed Assets | 381 | 393 | 383 | 489 | 605 | 719 | 745 | 804 |
| Other Non-Current Assets | 61 | 76 | 116 | 110 | 155 | 103 | 120 | 308 |
| Total Current Assets | 113 | 118 | 109 | 127 | 170 | 180 | 535 | 396 |
| Total Assets | 554 | 586 | 609 | 726 | 930 | 1002 | 1399 | 1508 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 4 | 9 | 12 | 19 | 16 | 23 | 15 | 42 |
| Cash Flow from Operating Activities | 40 | 56 | 27 | 60 | 127 | 109 | 156 | 132 |
| Cash Flow from Investing Activities | -50 | -26 | -37 | -107 | -158 | -88 | -393 | -90 |
| Cash Flow from Financing Activities | 14 | -27 | 18 | 44 | 38 | -29 | 264 | -50 |
| Net Cash Inflow / Outflow | 5 | 2 | 8 | -3 | 7 | -8 | 27 | -8 |
| Closing Cash & Cash Equivalent | 9 | 12 | 19 | 16 | 23 | 15 | 42 | 33 |
| # | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0 | 1.5 | 0.49 | 2.4 | 2.88 | 3.62 | 6 | 6.55 |
| CEPS(Rs) | 0 | 3.18 | 2.09 | 4.05 | 5.15 | 6.58 | 9.25 | 9.59 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0.45 | 0.45 | 0.45 | 0.45 |
| Book NAV/Share(Rs) | 0 | 18.68 | 19.17 | 21.51 | 24.43 | 27.52 | 55.63 | 54.69 |
| Core EBITDA Margin(%) | 11.68 | 10.88 | 8.62 | 11.98 | 12.74 | 15.1 | 16.2 | 17.4 |
| EBIT Margin(%) | 8.74 | 7.69 | 5.01 | 8.86 | 9.53 | 11.35 | 14.9 | 15.43 |
| Pre Tax Margin(%) | 6.72 | 5.42 | 1.84 | 6.7 | 6.86 | 7.79 | 11.49 | 12.87 |
| PAT Margin (%) | 3.73 | 3.44 | 1.51 | 5.66 | 5.15 | 5.59 | 8.77 | 9.59 |
| Cash Profit Margin (%) | 7.4 | 7.45 | 6.78 | 9.66 | 9.36 | 10.18 | 13.59 | 14.04 |
| ROA(%) | 3.68 | 3.41 | 1.03 | 4.71 | 4.59 | 5.09 | 6.84 | 7.14 |
| ROE(%) | 9.5 | 8.43 | 2.46 | 11.66 | 12.41 | 14.01 | 14.43 | 12.72 |
| ROCE(%) | 13.96 | 12.64 | 5.63 | 11.47 | 13.34 | 16.47 | 16.93 | 15.83 |
| Receivable days | 52.5 | 50.13 | 58.68 | 42.15 | 41.25 | 39.07 | 38.21 | 37.29 |
| Inventory Days | 4.63 | 5.71 | 9.11 | 7.24 | 6.53 | 5 | 3.91 | 3.95 |
| Payable days | 205.99 | 194.88 | 206.67 | 138.01 | 141.52 | 152.49 | 156.98 | 143.48 |
| PER(x) | 0 | 9.23 | 45.31 | 19.1 | 23.65 | 46.95 | 45.76 | 31.36 |
| Price/Book(x) | 0 | 0.74 | 1.16 | 2.13 | 2.79 | 6.17 | 4.94 | 3.75 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0.66 | 0.27 | 0.16 | 0.22 |
| EV/Net Sales(x) | 0.19 | 0.47 | 0.96 | 1.38 | 1.5 | 2.84 | 3.88 | 3.02 |
| EV/Core EBITDA(x) | 1.5 | 4.01 | 10.07 | 10.7 | 10.89 | 17.84 | 19.65 | 15 |
| Net Sales Growth(%) | 0 | 3.39 | -27.72 | 35.85 | 32.92 | 19.14 | 6.64 | 15.4 |
| EBIT Growth(%) | 0 | -9.04 | -52.9 | 140.33 | 42.97 | 41.91 | 39.98 | 19.52 |
| PAT Growth(%) | 0 | -4.55 | -68.35 | 409.76 | 21.05 | 29.29 | 67.21 | 26.21 |
| EPS Growth(%) | 0 | 0 | -67.23 | 390.47 | 19.75 | 25.68 | 66.01 | 9.01 |
| Debt/Equity(x) | 0.53 | 0.4 | 0.5 | 0.64 | 0.74 | 0.68 | 0.32 | 0.26 |
| Current Ratio(x) | 0.64 | 0.74 | 0.92 | 0.92 | 0.83 | 0.98 | 2.48 | 1.65 |
| Quick Ratio(x) | 0.6 | 0.68 | 0.84 | 0.83 | 0.76 | 0.92 | 2.43 | 1.6 |
| Interest Cover(x) | 4.34 | 3.39 | 1.58 | 4.11 | 3.57 | 3.19 | 4.37 | 6.03 |
| Total Debt/Mcap(x) | 0 | 0.54 | 0.43 | 0.3 | 0.26 | 0.11 | 0.07 | 0.07 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 68.03 | 67.51 | 67.17 | 67.17 | 67.17 | 66.53 | 66.53 | 58.39 | 58.39 | 58.39 |
| FII | 0.1 | 0.16 | 0.22 | 0.64 | 0.31 | 0.24 | 0.37 | 12.47 | 12.19 | 12.29 |
| DII | 9.78 | 10.57 | 10.69 | 11.59 | 12.13 | 11.78 | 11.29 | 9.07 | 9.05 | 8.56 |
| Public | 22.08 | 21.76 | 21.92 | 20.6 | 20.39 | 21.46 | 21.81 | 20.08 | 20.37 | 20.76 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 |
| FII | 0.01 | 0.02 | 0.03 | 0.09 | 0.04 | 0.03 | 0.05 | 1.97 | 1.93 | 1.95 |
| DII | 1.33 | 1.45 | 1.47 | 1.59 | 1.67 | 1.64 | 1.57 | 1.44 | 1.43 | 1.35 |
| Public | 3 | 2.98 | 3.02 | 2.83 | 2.81 | 2.98 | 3.03 | 3.18 | 3.22 | 3.29 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13.59 | 13.69 | 13.76 | 13.76 | 13.76 | 13.89 | 13.89 | 15.83 | 15.83 | 15.83 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +15% | +14% | +22% | — |
| Operating Profit CAGR | +18% | +29% | +41% | — |
| PAT CAGR | +27% | +40% | +77% | — |
| Share Price CAGR | +43% | +30% | +56% | — |
| ROE Average | +13% | +14% | +13% | +11% |
| ROCE Average | +16% | +16% | +15% | +13% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 68.03 | 67.51 | 67.17 | 67.17 | 67.17 | 66.53 | 66.53 | 58.39 | 58.39 | 58.39 |
| FII | 0.1 | 0.16 | 0.22 | 0.64 | 0.31 | 0.24 | 0.37 | 12.47 | 12.19 | 12.29 |
| DII | 9.78 | 10.57 | 10.69 | 11.59 | 12.13 | 11.78 | 11.29 | 9.07 | 9.05 | 8.56 |
| Public | 22.08 | 21.76 | 21.92 | 20.6 | 20.39 | 21.46 | 21.81 | 20.08 | 20.37 | 20.76 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 |
| FII | 0.01 | 0.02 | 0.03 | 0.09 | 0.04 | 0.03 | 0.05 | 1.97 | 1.93 | 1.95 |
| DII | 1.33 | 1.45 | 1.47 | 1.59 | 1.67 | 1.64 | 1.57 | 1.44 | 1.43 | 1.35 |
| Public | 3 | 2.98 | 3.02 | 2.83 | 2.81 | 2.98 | 3.03 | 3.18 | 3.22 | 3.29 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13.59 | 13.69 | 13.76 | 13.76 | 13.76 | 13.89 | 13.89 | 15.83 | 15.83 | 15.83 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.